PALI: Palisade Bio Inc. Price to Net Income Growth Ratio

Corporate company logo of palisadebio.com (PALI)

Palisade Bio, Inc. (PALI) minimizes risks through a diversified portfolio of targeted gastrointestinal drugs. The PEG ratio confirms this strategy, where 0.00 determines the latest valuation metric. Palisade Bio, Inc. (PALI) is developing unique protease inhibitors for post-surgical tissue protection, while its growth remains independent of macroeconomic cycles, relying instead on the success of clinical trials.

palisadebio.com (PALI): Price/Earnings to Growth Multiple from 07/04/2022 to 11/10/2026

Analytical breakdowns for Palisade Bio (PALI)

- share price and consensus valuation forecast:
Price Performance Chart palisadebio.com|PALI - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Palisade Bio|PALI - Enterprise Value
- book capitalization data:
Net Assets per Share Palisade Bio|PALI - Company Net Assets|Market Cap to Book Value Multiple palisadebio.com|PALI - Aggregate Company Assets
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Palisade Bio, Inc.|PALI - Long-Term Debt to Capital|Short-Term Debt to Capital Palisade Bio Inc.|PALI - Company Debts|Debt to Book Capitalization Ratio Palisade Bio|PALI - Company Long-Term Debts|Short-Term Debt Volume Palisade Bio|Interim Coverage Ratio palisadebio.com
- net income and valuation ratios data:
PALI - Net Profit|Projected Future Earnings Palisade Bio, Inc.|PALI - P/E Multiple|Price to Future Earnings Ratio palisadebio.com|PALI - PEG Multiple|Company Value to EBITDA Palisade Bio|PALI - Operating profit before deduction of amortization|Earnings per share for the trailing year Palisade Bio|PALI - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months palisadebio.com|PALI - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Palisade Bio, Inc.
Fundamental company analysis:palisadebio.com PALI
Flagship merchandise of Palisade Bio

Palisade Bio, Inc. (PALI) innovative protease inhibitors radically accelerate postoperative rehabilitation, creating high potential business value. An undervaluation analysis based on growth rates via the PEG ratio allows investors to determine if they are overpaying for development dynamics; a value below one signals that the asset is fundamentally undervalued relative to its market expansion.

Competing companies

PHAT (Phathom Pharma) - Growth-Adjusted Payback Ratio|PEG Multiple TERN (Terns Pharmaceuticals Inc)|Price to Net Income Growth Ratio Ironwood Pharma|Curanex - PEG Multiple|Growth-Adjusted Market Cap to Net Income Immuron Limited IMRN|EVOK (Evoke Pharma) - Price/Earnings to Growth Multiple|ENTO: Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio RedHill Biopharma Ltd|Jaguar Health Corp - Market Cap to Earnings and Growth Ratio|PEG Multiple BIOR|PEG Multiple morphictx.com (MORF)